生物科技是臺灣積極推動的新興產業之ㄧ。台灣為因應新興生物技術的演進，推動精準醫療、再生醫療、數位健康等新興產業，同時接軌國際生技產業創新研發的趨勢。本研究以個案為例，探討次世代基因檢測產品如何在創新醫療領域制定商業模式與創造價值，並制定如實驗室開發檢測服務（Laboratory Developed Tests and Services, LDTS）特管法，打造臺灣精準健康的創新產品與服務模式，成為國際級生醫產業研發創新的樞紐。本研究首先利用個案訪談了解公司通過其創新的技術，已經成功地定位自己為醫療診斷領域的技術先驅。進一步利用訪談結果來分析企業產品開發成果、營運策略、產業升級的輔助，以及未來發展的可行性。
本研究進一步以SWOT分析企業競爭優勢、關鍵要素，以及對經營策略的影響。面對高昂的研發成本、市場接受度的挑戰和外部經濟政策的不確定性，公司需要持續強化其技術優勢，同時靈活調整其市場和財務策略。此外，本研究以顧客價值主張圖分析並規劃對後續有益的策略建議，期望業者將領先市場的技術優勢有效並能獲得使用者的信任並快速提高市場滲透率。通過個案研究與分析，了解企業未來發展將依賴於其能否有效利用市場機會，應對威脅，並最大化其價值主張的實現。並透過持續的創新和市場策略調整，M公司有望在全球醫療市場中取得持續的成功和增長。

Taiwan has promoted emerging industries such as precision medicine, regenerative medicine, and digital health, while also aligning with the trend of innovative research and development in the international biotechnology industry. This study to explore how next-generation genetic testing products can formulate business models and create value in the field of innovative healthcare, and formulate Special Management Law such as Laboratory Developed Tests and Services (LDTS) to create innovative products and service models for precision health. This study first uses case interviews to understand how the company, through its innovative technology, has successfully positioned itself as a technology pioneer in the field of medical diagnosis.
In addition, SWOT analysis showing the company's competitive advantages, key factors, and their impact on business strategies. Faced with high R&D costs, the challenge of market acceptance, and the uncertainty of external economic policies, the company needs to continuously strengthen its technological advantages and flexibly adjust its market and financial strategies. With a customer value proposition map, hoping that the company will effectively lead the market's technological advantages, gain user trust, and quickly increase market penetration. Through case studies and analysis, it is understood that the future development of the company will depend on its ability to effectively utilize market opportunities, respond to threats, and maximize the realization of its value proposition.

1. 資誠聯合會計師事務所 (2018)，精準醫療發展現況與趨勢-全球篇。
2. 經濟部工業局 (2023)，生技產業白皮書。
3. 經濟部工業局 (2022)，生技產業白皮書。
4. 歐陽佩佳 (2010)，「創新醫療產品之商業模式及價值創造研究：以昌固生物科技之可擴張椎體強化系統為例」，台灣大學管理學院台大-復旦EMBA境外專班碩士論文。
5. 蔡佩芬 (2018)，「精準健康照護創新服務設計模式建構—以北市一家自費高階健康管理診所為例」，國立台灣大學公共衛生學院健康政策與管理研究逤碩士論文。
6. Barney, J. (1991), “Firm Resources and Sustained Competitive Advantage”, Journal of Management, 17(1), 99-120.
7. Callaway, E. (2014), Revolutionary Genome Sequencing Technologies — The $1,000 Genome.
8. Clarke, L., et al, (2012), “The 1000 Genomes Project: Data Management and Community Access”, Natural, Natural Methods (9), 459-462.
9. Hayden, E. C. (2014), “Technology: The $1,000 Genome”, PubMed, February.
10. Kordupleski, R (2003), “Mastering Customer Value Management: The Art and Science of Creating Competitive Advantage,” Customer Value Management I.
11. Mardis, E. R. (2013), “Next-generation Sequencing Platforms”, Annual Review of Analytical Chemistry, 6(1), 287-303.
12. Prahalad, C.K. & G. Hamel (1990), “The Core Competence of the Corporation”, Harvard Business Review, March.
13. Shendure, J., & H. Ji. (2008), “Next-generation DNA Sequencing”, Nature Biotechnology, 26, 1135-1145.
14. Shendure, J., & Ji, H.(2010), ”Next-generation DNA sequencing”, Genes, 1, 38-69.
15. Teece, D. J., G. Pisano & A. Shuen (1997), “Dynamic Capabilities and Strategic Management”, Strategic Management Journal, 18(7), 509-533.